Top-Rated Stocks NASDAQ:GH Guardant Health - GH Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Guardant Health, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $31.48 +0.41 (+1.32%) (As of 01/27/2023 12:00 AM ET) Add Compare Share Share Today's Range$30.59▼$31.8850-Day Range$25.44▼$53.8152-Week Range$24.63▼$78.34Volume1.00 million shsAverage Volume1.45 million shsMarket Capitalization$3.22 billionP/E RatioN/ADividend YieldN/APrice Target$90.39 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability Guardant Health MarketRank™ ForecastAnalyst RatingModerate Buy2.94 Rating ScoreUpside/Downside187.2% Upside$90.39 Price TargetShort InterestBearish5.74% of Float Sold ShortDividend StrengthN/ASustainability-0.95Upright™ Environmental ScoreNews Sentiment1.34Based on 6 Articles This WeekInsider TradingSelling Shares$162,094 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($6.46) to ($5.19) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.71 out of 5 starsMedical Sector75th out of 1,049 stocksMedical Laboratories Industry3rd out of 25 stocks 4.5 Analyst's Opinion Consensus RatingGuardant Health has received a consensus rating of Buy. The company's average rating score is 2.94, and is based on 15 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $90.39, Guardant Health has a forecasted upside of 187.2% from its current price of $31.48.Amount of Analyst CoverageGuardant Health has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.0 Short Interest Percentage of Shares Shorted5.74% of the float of Guardant Health has been sold short.Short Interest Ratio / Days to CoverGuardant Health has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Guardant Health has recently increased by 8.82%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldGuardant Health does not currently pay a dividend.Dividend GrowthGuardant Health does not have a long track record of dividend growth. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreGuardant Health has received a 66.04% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Genomics analysis tools" and "Clinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Guardant Health is -0.95. Previous Next 3.5 News and Social Media Coverage News SentimentGuardant Health has a news sentiment score of 1.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.72 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Guardant Health this week, compared to 2 articles on an average week.Search InterestOnly 8 people have searched for GH on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat Follows6 people have added Guardant Health to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Guardant Health insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $162,094.00 in company stock.Percentage Held by InsidersOnly 5.90% of the stock of Guardant Health is held by insiders.Percentage Held by Institutions90.43% of the stock of Guardant Health is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Guardant Health are expected to grow in the coming year, from ($6.46) to ($5.19) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Guardant Health is -5.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Guardant Health is -5.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGuardant Health has a P/B Ratio of 4.96. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Guardant Health (NASDAQ:GH) StockGuardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing LUNAR-2 test for the early detection of colorectal cancer in asymptomatic individuals eligible; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials. In addition, the company offers Guardant Reveal Test for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; Guardant360 tissue genotyping product; and Guardant-19 for use in the detection of the novel coronavirus. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, and kits fulfillment related services to biopharmaceutical companies and medical institutions. The company was incorporated in 2011 and is headquartered in Redwood City, California.Read More Receive GH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Guardant Health and its competitors with MarketBeat's FREE daily newsletter. Email Address GH Stock News HeadlinesJanuary 29, 2023 | finance.yahoo.comGuardant Health (NASDAQ:GH) investors are sitting on a loss of 59% if they invested three years agoJanuary 23, 2023 | americanbankingnews.comShort Interest in Guardant Health, Inc. (NASDAQ:GH) Increases By 18.9%January 29, 2023 | Porter & Company (Ad)The Next Big Crisis Is HereYou just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.January 20, 2023 | seekingalpha.comGuardant Health: Positive ECLIPSE Data Signals More UpsideJanuary 20, 2023 | americanbankingnews.comComparing Guardant Health (NASDAQ:GH) & MDxHealth (NASDAQ:MDXH)January 19, 2023 | americanbankingnews.comGuardant Health, Inc. (NASDAQ:GH) Receives $90.39 Average PT from AnalystsJanuary 18, 2023 | reuters.comGH.OQ - | Stock Price & Latest News | ReutersJanuary 17, 2023 | finance.yahoo.comGuardant Health to showcase new data at ASCO GI 2023 demonstrating utility of its blood tests for patients with gastrointestinal cancersJanuary 29, 2023 | Porter & Company (Ad)Is This The End of Capitalism?EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…January 9, 2023 | msn.comGuardant health gains on guiding Q4 and FY22 revenue above estimatesDecember 28, 2022 | finance.yahoo.comGuardant Health Looks Downright SicklyDecember 21, 2022 | forbes.comIs A Rise Imminent For Guardant Health Stock After A 38% Fall In A Month?December 16, 2022 | bizjournals.comGuardant Health lost 27% of its stock valuation after releasing study on its colorectal cancer blood testDecember 16, 2022 | finance.yahoo.comMidday movers: Adobe Systems, Guardant Health, Meta Platforms and moreDecember 16, 2022 | msn.comExact at seven-month high as Guardant data for cancer screening test disappointsDecember 16, 2022 | proactiveinvestors.comGuardant Health stock plunges, Exact Sciences rises on contrasting colorectal cancer detection testsDecember 16, 2022 | msn.comGuardant DNA blood test finds 83% of colorectal cancers in trial, shares fall 35%December 15, 2022 | msn.comGuardant DNA blood test finds 83% of colorectal cancers in trial, shares fall 39%November 18, 2022 | benzinga.comGuardant Health Recent Insider ActivityNovember 15, 2022 | benzinga.comGuardant Health Unusual Options ActivityNovember 9, 2022 | finance.yahoo.comGuardant Health Third Quarter 2022 Earnings: EPS Misses ExpectationsNovember 7, 2022 | seekingalpha.comGuardant: A Temporary Exemption From The Gene Testing Market New ParadigmNovember 1, 2022 | finance.yahoo.comDown More Than 50%: These 3 “Strong Buy” Stocks Are Too Cheap to IgnoreOctober 17, 2022 | forbes.comBlood Test For Cancer Gives New Life To Guardant Health SharesOctober 16, 2022 | seekingalpha.comGuardant: Saving Lives One Blood Test At A TimeOctober 11, 2022 | seekingalpha.comGH Guardant Health, Inc.October 11, 2022 | health.usnews.comEast Jefferson General HospitalSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive GH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Guardant Health and its competitors with MarketBeat's FREE daily newsletter. Email Address GH Company Calendar Last Earnings11/03/2022Today1/29/2023Next Earnings (Estimated)2/22/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Medical laboratories Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:GH CUSIPN/A CIK1576280 Webwww.guardanthealth.com Phone(855) 698-8887Fax888-974-4258Employees1,373Year FoundedN/APrice Target and Rating Average Stock Price Forecast$90.39 High Stock Price Forecast$165.00 Low Stock Price Forecast$36.00 Forecasted Upside/Downside+187.2%Consensus RatingModerate Buy Rating Score (0-4)2.94 Research Coverage16 Analysts Profitability EPS (Most Recent Fiscal Year)($5.93) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-405,670,000.00 Net Margins-140.58% Pretax Margin-136.14% Return on Equity-145.58% Return on Assets-30.70% Debt Debt-to-Equity Ratio6.82 Current Ratio6.46 Quick Ratio6.10 Sales & Book Value Annual Sales$373.65 million Price / Sales8.63 Cash FlowN/A Price / Cash FlowN/A Book Value$6.34 per share Price / Book4.96Miscellaneous Outstanding Shares102,440,000Free Float96,392,000Market Cap$3.22 billion OptionableNot Optionable Beta0.83 Key ExecutivesDr. Helmy Eltoukhy Ph.D. (Age 44)Co-Founder, Co-CEO & Chairman Comp: $13.66kDr. AmirAli Talasaz Ph.D. (Age 43)Co-CEO & Director Comp: $13.27kMr. Michael Bell (Age 54)Chief Financial Officer Comp: $1.2MMr. John G. Saia (Age 50)Chief Legal Officer Comp: $641.22kDr. Craig Eagle M.D. (Age 56)Chief Medical Officer Comp: $2.88MMr. Christopher Freeman (Age 49)Chief Commercial Officer of Oncology Bus. Comp: $740.23kMr. Andy AmentSr. VP of OperationsDarya ChudovaSr. VP of TechnologyMr. Kumud KaliaChief Information OfficerMs. Jennifer HigginsVP of Public AffairsMore ExecutivesKey CompetitorsNateraNASDAQ:NTRAVeracyteNASDAQ:VCYTRadNetNASDAQ:RDNTViridian TherapeuticsNASDAQ:VRDNFulgent GeneticsNASDAQ:FLGTView All CompetitorsInsiders & InstitutionsSicart Associates LLCSold 38,469 shares on 1/27/2023Ownership: 0.096%MGO One Seven LLCBought 4,163 shares on 1/25/2023Ownership: 0.010%Fifth Third BancorpSold 526 shares on 1/25/2023Ownership: 0.006%Oak Ridge Investments LLCSold 647 shares on 1/24/2023Ownership: 0.023%Xponance Inc.Bought 1,398 shares on 1/24/2023Ownership: 0.013%View All Insider TransactionsView All Institutional Transactions GH Stock - Frequently Asked Questions Should I buy or sell Guardant Health stock right now? 16 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Guardant Health in the last twelve months. There are currently 1 hold rating and 15 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" GH shares. View GH analyst ratings or view top-rated stocks. What is Guardant Health's stock price forecast for 2023? 16 Wall Street analysts have issued 12-month price objectives for Guardant Health's stock. Their GH share price forecasts range from $36.00 to $165.00. On average, they anticipate the company's stock price to reach $90.39 in the next twelve months. This suggests a possible upside of 187.2% from the stock's current price. View analysts price targets for GH or view top-rated stocks among Wall Street analysts. How have GH shares performed in 2023? Guardant Health's stock was trading at $27.20 at the beginning of 2023. Since then, GH stock has increased by 15.7% and is now trading at $31.4750. View the best growth stocks for 2023 here. When is Guardant Health's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 22nd 2023. View our GH earnings forecast. How were Guardant Health's earnings last quarter? Guardant Health, Inc. (NASDAQ:GH) issued its earnings results on Thursday, November, 3rd. The company reported ($1.58) earnings per share for the quarter, missing the consensus estimate of ($1.27) by $0.31. The company earned $117.40 million during the quarter, compared to the consensus estimate of $118.18 million. Guardant Health had a negative net margin of 140.58% and a negative trailing twelve-month return on equity of 145.58%. What guidance has Guardant Health issued on next quarter's earnings? Guardant Health updated its FY 2022 earnings guidance on Monday, January, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $447.00 million-$450.00 million, compared to the consensus revenue estimate of $445.24 million. What is Helmy Eltoukhy's approval rating as Guardant Health's CEO? 52 employees have rated Guardant Health Chief Executive Officer Helmy Eltoukhy on Glassdoor.com. Helmy Eltoukhy has an approval rating of 95% among the company's employees. This puts Helmy Eltoukhy in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Guardant Health own? Based on aggregate information from My MarketBeat watchlists, some companies that other Guardant Health investors own include NVIDIA (NVDA), Trade Desk (TTD), Block (SQ), Alibaba Group (BABA), PayPal (PYPL), Shopify (SHOP), Okta (OKTA), Alteryx (AYX), Roku (ROKU) and Twilio (TWLO). When did Guardant Health IPO? (GH) raised $200 million in an IPO on Thursday, October 4th 2018. The company issued 12,500,000 shares at $15.00-$17.00 per share. J.P. Morgan and BofA Merrill Lynch acted as the underwriters for the IPO and Cowen, Leerink Partners and William Blair were co-managers. What is Guardant Health's stock symbol? Guardant Health trades on the NASDAQ under the ticker symbol "GH." Who are Guardant Health's major shareholders? Guardant Health's stock is owned by a number of institutional and retail investors. Top institutional shareholders include ARK Investment Management LLC (0.49%), Sicart Associates LLC (0.10%), Exchange Traded Concepts LLC (0.03%), Oak Ridge Investments LLC (0.02%), Values First Advisors Inc. (0.01%) and Xponance Inc. (0.01%). Insiders that own company stock include Amelia Merrill, Amirali Talasaz, Bluebird (Cayman) Ltd Svf, Derek A Bertocci, Helmy Eltoukhy, Ian T Clark, Kumud Kalia, Michael J Wiley, Samir Kaul, Stanley J Meresman and Stanley J Meresman. View institutional ownership trends. How do I buy shares of Guardant Health? Shares of GH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Guardant Health's stock price today? One share of GH stock can currently be purchased for approximately $31.48. How much money does Guardant Health make? Guardant Health (NASDAQ:GH) has a market capitalization of $3.22 billion and generates $373.65 million in revenue each year. The company earns $-405,670,000.00 in net income (profit) each year or ($5.93) on an earnings per share basis. How many employees does Guardant Health have? The company employs 1,373 workers across the globe. How can I contact Guardant Health? Guardant Health's mailing address is 505 PENOBSCOT DR., REDWOOD CITY CA, 94063. The official website for the company is www.guardanthealth.com. The company can be reached via phone at (855) 698-8887, via email at investors@guardanthealth.com, or via fax at 888-974-4258. This page (NASDAQ:GH) was last updated on 1/29/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.